New England Journal of Medicine,
Journal Year:
2023,
Volume and Issue:
389(24), P. 2221 - 2232
Published: Nov. 11, 2023
BackgroundSemaglutide,
a
glucagon-like
peptide-1
receptor
agonist,
has
been
shown
to
reduce
the
risk
of
adverse
cardiovascular
events
in
patients
with
diabetes.
Whether
semaglutide
can
associated
overweight
and
obesity
absence
diabetes
is
unknown.MethodsIn
multicenter,
double-blind,
randomized,
placebo-controlled,
event-driven
superiority
trial,
we
enrolled
45
years
age
or
older
who
had
preexisting
disease
body-mass
index
(the
weight
kilograms
divided
by
square
height
meters)
27
greater
but
no
history
Patients
were
randomly
assigned
1:1
ratio
receive
once-weekly
subcutaneous
at
dose
2.4
mg
placebo.
The
primary
end
point
was
composite
death
from
causes,
nonfatal
myocardial
infarction,
stroke
time-to-first-event
analysis.
Safety
also
assessed.Download
PDF
Research
Summary.ResultsA
total
17,604
enrolled;
8803
8801
mean
(±SD)
duration
exposure
placebo
34.2±13.7
months,
follow-up
39.8±9.4
months.
A
end-point
event
occurred
569
(6.5%)
group
701
(8.0%)
(hazard
ratio,
0.80;
95%
confidence
interval,
0.72
0.90;
P<0.001).
Adverse
leading
permanent
discontinuation
trial
product
1461
(16.6%)
718
(8.2%)
(P<0.001).ConclusionsIn
without
diabetes,
weekly
superior
reducing
incidence
39.8
(Funded
Novo
Nordisk;
SELECT
ClinicalTrials.gov
number,
NCT03574597.)
Quick
Take
Semaglutide
Cardiovascular
Outcomes
Obesity
2m
17s
Circulation,
Journal Year:
2024,
Volume and Issue:
149(8)
Published: Jan. 24, 2024
BACKGROUND:
The
American
Heart
Association
(AHA),
in
conjunction
with
the
National
Institutes
of
Health,
annually
reports
most
up-to-date
statistics
related
to
heart
disease,
stroke,
and
cardiovascular
risk
factors,
including
core
health
behaviors
(smoking,
physical
activity,
nutrition,
sleep,
obesity)
factors
(cholesterol,
blood
pressure,
glucose
control,
metabolic
syndrome)
that
contribute
health.
AHA
Disease
Stroke
Statistical
Update
presents
latest
data
on
a
range
major
clinical
circulatory
disease
conditions
(including
brain
health,
complications
pregnancy,
kidney
congenital
rhythm
disorders,
sudden
cardiac
arrest,
subclinical
atherosclerosis,
coronary
cardiomyopathy,
failure,
valvular
venous
thromboembolism,
peripheral
artery
disease)
associated
outcomes
quality
care,
procedures,
economic
costs).
METHODS:
AHA,
through
its
Epidemiology
Prevention
Statistics
Committee,
continuously
monitors
evaluates
sources
stroke
United
States
globally
provide
current
information
available
annual
review
published
literature
year
before
writing.
2024
is
product
full
year’s
worth
effort
2023
by
dedicated
volunteer
clinicians
scientists,
committed
government
professionals,
staff
members.
strives
further
understand
help
heal
problems
inflicted
structural
racism,
public
crisis
can
significantly
damage
mental
perpetuate
disparities
access
education,
income,
housing,
several
other
vital
healthy
lives.
This
edition
includes
additional
global
data,
as
well
monitoring
benefits
population,
an
enhanced
focus
equity
across
key
domains.
RESULTS:
Each
chapters
focuses
different
topic
statistics.
CONCLUSIONS:
represents
critical
resource
for
lay
public,
policymakers,
media
clinicians,
care
administrators,
researchers,
advocates,
others
seeking
best
these
conditions.
Circulation,
Journal Year:
2023,
Volume and Issue:
148(20), P. 1606 - 1635
Published: Oct. 9, 2023
Cardiovascular-kidney-metabolic
health
reflects
the
interplay
among
metabolic
risk
factors,
chronic
kidney
disease,
and
cardiovascular
system
has
profound
impacts
on
morbidity
mortality.
There
are
multisystem
consequences
of
poor
cardiovascular-kidney-metabolic
health,
with
most
significant
clinical
impact
being
high
associated
incidence
disease
events
is
a
prevalence
in
population,
disproportionate
burden
seen
those
adverse
social
determinants
health.
However,
there
also
growing
number
therapeutic
options
that
favorably
affect
function,
or
both
have
cardioprotective
effects.
To
improve
related
outcomes
critical
need
for
(1)
more
clarity
definition
syndrome;
(2)
an
approach
to
staging
promotes
prevention
across
life
course;
(3)
prediction
algorithms
include
exposures
relevant
health;
(4)
strategies
management
relation
reflect
harmonization
major
subspecialty
guidelines
emerging
scientific
evidence.
It
incorporate
considerations
into
care
models
syndrome
reduce
fragmentation
by
facilitating
approaches
patient-centered
interdisciplinary
care.
This
presidential
advisory
provides
guidance
definition,
staging,
paradigms,
holistic
patients
details
multicomponent
vision
effectively
equitably
enhancing
population.
Journal of Obesity & Metabolic Syndrome,
Journal Year:
2023,
Volume and Issue:
32(3), P. 197 - 213
Published: Sept. 13, 2023
Metabolic
dysfunction-associated
steatotic
liver
disease
(MASLD)
is
the
latest
term
for
associated
with
metabolic
syndrome.
MASLD
most
common
cause
of
chronic
and
leading
liver-related
morbidity
mortality.
It
important
that
all
stakeholders
be
involved
in
tackling
public
health
threat
obesity
obesity-related
diseases,
including
MASLD.
A
simple
clear
assessment
referral
pathway
using
non-invasive
tests
essential
to
ensure
patients
severe
are
identified
referred
specialist
care,
while
less
remain
primary
where
they
best
managed.
While
lifestyle
intervention
cornerstone
management
MASLD,
cardiovascular
risk
must
properly
assessed
managed
because
No
pharmacological
agent
has
been
approved
treatment
but
novel
anti-hyperglycemic
drugs
appear
have
benefit.
Medications
used
diabetes
other
conditions
may
need
adjusted
as
progresses
cirrhosis,
especially
decompensated
cirrhosis.
Based
on
tests,
concepts
compensated
advanced
clinically
significant
portal
hypertension
provide
a
practical
approach
stratifying
according
complications
can
help
manage
such
patients.
Finally,
prevention
sarcopenia
should
considered
Circulation,
Journal Year:
2023,
Volume and Issue:
148(20), P. 1636 - 1664
Published: Oct. 9, 2023
A
growing
appreciation
of
the
pathophysiological
interrelatedness
metabolic
risk
factors
such
as
obesity
and
diabetes,
chronic
kidney
disease,
cardiovascular
disease
has
led
to
conceptualization
cardiovascular-kidney-metabolic
syndrome.
The
confluence
within
syndrome
is
strongly
linked
for
adverse
outcomes.
In
addition,
there
are
unique
management
considerations
individuals
with
established
coexisting
factors,
or
both.
An
extensive
body
literature
supports
our
scientific
understanding
of,
approach
to,
prevention
However,
critical
gaps
in
knowledge
related
terms
mechanisms
development,
heterogeneity
clinical
phenotypes,
interplay
between
social
determinants
health
biological
accurate
assessments
incidence
context
competing
risks.
There
also
key
limitations
data
supporting
care
syndrome,
particularly
early-life
prevention,
screening
interdisciplinary
models,
optimal
strategies
lifestyle
modification
weight
loss,
targeting
emerging
cardioprotective
kidney-protective
therapies,
patients
both
impact
systematically
assessing
addressing
health.
This
statement
uses
a
crosswalk
major
guidelines,
addition
review
literature,
summarize
evidence
fundamental
science,
screening,
Circulation,
Journal Year:
2023,
Volume and Issue:
148(24), P. 1982 - 2004
Published: Nov. 10, 2023
Cardiovascular-kidney-metabolic
(CKM)
syndrome
is
a
novel
construct
recently
defined
by
the
American
Heart
Association
in
response
to
high
prevalence
of
metabolic
and
kidney
disease.
Epidemiological
data
demonstrate
higher
absolute
risk
both
atherosclerotic
cardiovascular
disease
(CVD)
heart
failure
as
an
individual
progresses
from
CKM
stage
0
3,
but
optimal
strategies
for
assessment
need
be
refined.
Absolute
with
goal
match
type
intensity
interventions
predicted
expected
treatment
benefit
remains
cornerstone
primary
prevention.
Given
growing
number
therapies
our
armamentarium
that
simultaneously
address
all
3
axes,
prediction
equations
are
needed
incorporate
predictors
outcomes
relevant
context.
This
should
also
include
social
determinants
health,
which
key
upstream
drivers
CVD,
more
equitably
estimate
risk.
scientific
statement
summarizes
background,
rationale,
clinical
implications
newly
developed
sex-specific,
race-free
equations:
PREVENT
(AHA
Predicting
Risk
CVD
Events).
The
enable
10-
30-year
estimates
total
(composite
failure),
estimated
glomerular
filtration
rate
predictor,
adjust
competing
non-CVD
death
among
adults
30
79
years
age.
Additional
models
accommodate
enhanced
predictive
utility
addition
factors
when
clinically
indicated
measurement
(urine
albumin-to-creatinine
ratio
hemoglobin
A1c)
or
health
(social
deprivation
index)
available.
Approaches
implement
risk-based
prevention
using
across
various
settings
discussed.
Diabetes & Metabolism Journal,
Journal Year:
2023,
Volume and Issue:
47(5), P. 575 - 594
Published: Sept. 26, 2023
In
May
2023,
the
Committee
of
Clinical
Practice
Guidelines
Korean
Diabetes
Association
published
revised
clinical
practice
guidelines
for
adults
with
diabetes
and
prediabetes.
We
incorporated
latest
research
findings
through
a
comprehensive
systematic
literature
review
applied
them
in
manner
suitable
population.
These
are
designed
all
healthcare
providers
nationwide,
including
physicians,
experts,
certified
educators
who
manage
patients
or
individuals
at
risk
developing
diabetes.
Based
on
recent
changes
international
results
epidemiological
study,
recommended
age
screening
has
been
lowered.
collaboration
relevant
medical
societies,
recently
managing
hypertension
dyslipidemia
have
into
this
guideline.
An
abridgment
containing
practical
information
patient
education
management
clinic
was
separately.
BMJ,
Journal Year:
2024,
Volume and Issue:
unknown, P. e076388 - e076388
Published: Feb. 13, 2024
Abstract
Objective
To
investigate
the
risk
of
non-alcoholic
fatty
liver
disease
(NAFLD)
for
cardiovascular
and
all
cause
death
in
patients
with
type
2
diabetes
mellitus
(T2DM).
Design
Nationwide
population
based
study.
Setting
Longitudinal
cohort
study
Korea.
Participants
7
796
763
participants
National
Health
Screening
Programme
2009
were
divided
into
three
groups
on
NAFLD
status:
no
(fatty
index<30);
grade
1
(30≤fatty
index<60);
index≥60).
Median
follow-up
was
8.13
years.
Main
outcome
measures
The
primary
incident
(myocardial
infarction,
ischaemic
stroke)
or
death.
Results
Of
participants,
6.49%
(n=505
763)
had
T2DM.
More
T2DM
(34.06%)
(26.73%)
than
those
without
(grade
NAFLD:
21.20%;
10.02%).
incidence
rate
(per
1000
person
years)
increased
order
NAFLD,
rates
higher
five
year
absolute
(no
T2DM:
1.03,
95%
confidence
interval
1.02
to
1.04,
1.25,
1.24
1.26,
respectively;
1.23,
1.22
1.50,
1.48
1.51,
1.42,
1.40
1.45,
2.09,
2.06
2.12,
3.34,
3.27
3.41,
3.68,
3.61
3.74,
3.94,
3.87
4.02,
4.25,
4.18
4.33,
4.66,
4.54
4.78,
5.91,
5.78
6.05,
respectively).
Patients
a
NAFLD.
Risk
differences
between
Conclusions
seems
be
associated
death,
even
mild
group
